Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

NCT00479674 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Abraxane
DRUG: Bevacizumab
DRUG: Carboplatin

Sponsor

Duke University

Collaborators

[object Object]
[object Object]